Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer

Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits.

Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment.

In intra-day trading, the stock climbed to a record high of $23.09 before trimming gains to end the day just up by 16.37 percent at $22.46 apiece.

In a statement, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it joined forces with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton's tyrosine kinase (BTK).

According to the two parties, the collaboration encompasses a comprehensive clinical development plan spanning malignant hematology, immunology and neurology intended to explore the full clinical potential of BTK degradation across diverse patient populations. In addition to the Phase 2 and Phase 3 trials in chronic lymphocytic leukemia, the collaboration plans to pursue multiple label-enabling studies across a range of malignant hematology indications as monotherapy and in combination regimens,  and expan

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/nurix-nrix-climbs-52-week-031417271.html)